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ABSTRACT 
 
Sarah Radke: HIV and Hepatitis B Co-infection: Recent Improvements in Short-term 
Mortality and Effect of Modern Therapy on HIV Outcomes 
(Under the direction of Sonia Napravnik) 
 
 
Hepatitis B virus (HBV) co-infection increases morbidity and mortality among HIV-
infected individuals. US treatment guidelines recommend initial antiretroviral therapy (ART) 
for HIV/HBV co-infected patients include agents active against both HIV and HBV, in 
particular tenofovir disoproxil fumerate (TDF), based on its efficacy against HBV outcomes. 
Few studies have examined the comparative effectiveness of TDF-containing ART regimens 
versus regimens without TDF on HIV outcomes in co-infected patients. To examine the 
relationship between HBV co-infection and all-cause mortality, we examined data on 3,706 
HIV-infected individuals enrolled in the Centers for AIDS Research Network of Integrated 
Clinical Systems (CNICS) who began ART during three periods: 1998-2001, 2002-2004 and 
2005-2008. Time to mortality hazard ratios comparing HBV-infected and HBV-uninfected 
patients were 2.20 (95% Confidence Interval [CI]: 0.92, 5.23), 2.09 (95% CI: 0.86, 5.07) and 
0.96 (95% CI:0.29, 3.16) for patients initiating therapy in 1998-2001, 2002-2004 and 2005-
2008 respectively, adjusted for baseline demographic and clinical characteristics. To examine 
the effect of TDF on HIV virologic and immunologic response, we examined the 212 (6%) 
HBV co-infected patients in the CNICS cohort. TDF use was associated with superior HIV 
RNA response during the first 19 months of ART, with an adjusted hazard ratio for time to 
HIV virologic failure comparing patients without TDF use to patients with TDF use of 2.26 
(95% CI: 1.1.8, 4.34). No effect of TDF use on time to HIV virologic failure was seen after 
  iv   
patients had consistent HIV RNA suppression for more than 19 months (adjusted hazard 
ratio=0.44, 95% CI: 0.15, 1.31). We did not observe an effect of TDF use on CD4 count 
response. Our findings help in identifying the optimal therapeutic management of HIV/HBV 
co-infected patients, which is not only relevant to individuals living in the US, but is also 
increasingly relevant to areas of the world where HBV is endemic and modern ART is 
increasingly available. Efforts to expand the use of agents efficacious against both HIV and 
HBV are needed, as well as careful monitoring to ensure the positive benefits seen in our 
studies are also seen for HIV/HBV co-infected patients living in resource limited settings. 
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CHAPTER ONE: SPECIFIC AIMS 
 
Human immunodeficiency virus (HIV)/hepatitis B (HBV) co-infected individuals may 
have inferior response to therapy and long-term clinical outcomes compared to HIV-infected 
individuals. The widespread use of modern antiretroviral therapy (ART) has substantially 
decreased HIV-related morbidity and mortality, and non-AIDS events, including liver-related 
complications caused by HBV infection, are increasingly important to HIV clinical care.1-5 
Additionally, ART may have unintended effects including hepatotoxicity which may be 
higher among HBV co-infected individuals.  On the other hand, some antiretroviral agents, in 
particular tenofovir disoproxil fumerate (TDF), emtricitabine (FTC) and lamivudine (3TC), 
have activity against both HIV and HBV, and when included as part of ART may mitigate 
HBV-induced liver damage. While the effect of HIV on HBV has been well elucidated (HIV 
affects HBV by increasing the risk of liver disease and hepatocellular carcinoma, and the rate 
of HBV reactivation), the impact of HBV on the progression of HIV and response to therapy 
remains debated.6,7     
We assessed the effect of HBV co-infection on time to all-cause mortality. Further, 
among HIV/HBV co-infected individuals, we examined whether, and to what extent, TDF 
affects response to initial ART, specifically HIV RNA suppression and CD4 count response. 
We used data from the Centers for AIDS Research (CFAR) Network of Integrated Clinical 
Systems (CNICS) study, which is a large HIV clinical cohort including eight sites across the 
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United States. Our specific aims were:  
Specific Aim 1  
Among ART-naïve HIV-infected individuals, assess the impact of HBV co-infection on 
time to mortality. 
a. Compare demographic and clinical characteristics by HBV co-infection status. 
Independent predictors of HBV co-infection at time of ART initiation were assessed 
using multivariable log-linear binomial regression. Patient demographic and clinical 
characteristics at ART initiation considered as potential predictors were age, sex, 
race/ethnicity, HIV risk transmission group, year of ART initiation, initial ART regimen 
anchor drug, AIDS defining clinical condition, hepatitis C virus (HCV) co-infection 
status, aspartate aminotransferase (AST)-to-platelet ratio index (APRI) score, HIV RNA 
level, CD4 count, creatinine level and CNICS site. 
b. Determine differences in time to mortality by HBV co-infection status stratified by 
calendar interval of therapy initiation. HBV co-infection was defined as a positive 
hepatitis B surface antigen (HBsAg) or HBV DNA result prior to beginning therapy. 
Mortality included deaths from any cause. Calendar time was divided into three intervals: 
1998-2001; 2002-2004; and 2005-2008. Multivariable Cox proportional hazard models 
were fit for each calendar interval, adjusting for the variables listed above in aim 1a.  
 
Hypothesis: HIV/HBV co-infected patients compared to HIV mono-infected patients will be 
older, more likely to be men who have sex with men (MSM), have a history of intravenous 
drug use (IVDU) and HCV co-infection, and have higher APRI levels. HBV co-infection will 
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be associated with a higher risk of death and shorter time to mortality, but this risk will 
decrease over calendar time. 
Specific Aim 2 
Among ART-naïve HIV/HBV co-infected patients, assess response to ART by TDF 
receipt. 
a. Compare demographic and clinical characteristics by TDF receipt. Independent 
predictors of TDF use were assessed using multivariable log-linear binomial regression. 
Patient demographic and clinical characteristics considered as potential predictors are 
listed above in aim 1a. 
b.  Evaluate HIV virologic and immunologic response to ART by TDF receipt. Our 
main exposure was inclusion of TDF in initial ART, either alone or in combination with 
FTC or 3TC. HIV virologic failure was defined as having two successive HIV RNA 
values >400 copies/mL after 16-weeks of ART exposure. The first date where HIV RNA 
was >400 copies/mL was used as the date of HIV virologic failure. Multivariable Cox 
proportional hazard models were fit adjusting for the variables listed above in aim 1a. 
Linear regression fit with generalized estimating equations was used to estimate the 
association between TDF use and CD4 count response.  
 
Hypothesis: HIV/HBV co-infected patients who received TDF (either TDF alone or in 
combination with 3TC or FTC) will have superior virologic and immunologic outcomes 
compared to patients who received ART regimens not including TDF.  
 
  
 
 
CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
HIV Infection 
HIV infection remains a leading cause of illness and death in the United States. Among 
the 40 million people in the world infected with HIV/AIDS, there are approximately 1.1 
million people infected in the United States, where it is estimated that 56,000 new cases 
occur annually.8 HIV increasingly affects women, racial and ethnic minorities and those who 
acquire HIV through heterosexual contact.9-11 HIV is transmitted between individuals by 
percutaneous or mucous membrane exposure to infective blood or other body fluids.12 Since 
the introduction of ART in 1996, HIV-infected individuals are living longer and experiencing 
more non-AIDS defining illnesses. As a result, liver disease has arisen as an important source 
of morbidity and mortality among the HIV-infected population.2-5 
 
Hepatitis B Infection 
HBV infection is widespread, yet largely goes unreported. Like HIV, HBV is 
transmitted via body fluids, but HBV is 50-100 times more infectious than HIV.13 Two 
billion people worldwide have been infected with HBV and nearly 400 million live with 
chronic infection.13 Overall 800,000 to 1.4 million individuals in the United States are living 
with chronic HBV infection.14 In the US, the incidence of HBV has declined steadily since 
the 1980s due to the introduction of the HBV vaccine, which became part of the routine 
immunization schedule in 1991. The incidence of HBV dropped from 8.5 cases per 100,000 
 5 
 
in 1990 to 2.8 cases per 100,000 in 2002.15 However, because HBV infection is often 
asymptomatic and may go unreported, the actual number of new infections is estimated to be 
approximately tenfold higher (figure 2.1).14 HBV is most common among adults 25-44 years 
old.16 
Acute HBV infection rarely leads to long-term morbidity, but chronic HBV leads to 
significant morbidity and mortality. Less than 1% of acute HBV patients develop liver 
failure.17 Resolution of the infection is achieved if an adequate immune response is mounted. 
However, individuals with a weak or ineffective immune response may develop chronic 
HBV.  In chronically infected patients, the continued expression of inflammatory cytokines 
and recruitment of activated lymphomononuclear cells to the liver result in fibrosis, cirrhosis 
and hepatocellular carcinoma (HCC).18-21 Liver damage is not caused by the direct action of 
the HBV, but rather by the immune response against the viral antigens. In other words, liver 
disease is related to cell-mediated immunity and inflammation rather than being directly 
cytopathic for hepatocytes.22 How quickly liver damage progresses depends on patients’ age, 
gender, immune status and on environmental factors.18,23-25  
Fibrosis, cirrhosis and HCC are more likely to lead to death in HBV-infected 
individuals than in healthy individuals. The risk of death due to cirrhosis among HBV-
infected individuals is nine times that of non-HBV infected individuals.18 The risk of death 
due to HCC among HBV-infected individuals is more than 100 times that of non-HBV 
infected individuals.26 Overall, it is estimated that 15-25% of patients infected with chronic 
HBV will die prematurely due to various liver complications.27 The likelihood of death 
depends on the severity of liver disease and effectiveness of therapy. Several factors 
influence disease severity, including older age, necroinflammation and fibrosis stage at 
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histology, ongoing HBV replication, and CD4 depletion.2,28,29 As a patient’s 
immunodeficiency progresses, disease and response to therapy worsen.30 
HBV treatment is suppressive rather than curative.  HBV treatment objectives include 
alanine aminotransferase normalization, improvement in liver histology and sustained 
suppression of serum HBV DNA.30-34 Successful treatment lowers liver inflammation, 
reverses liver fiborsis and reduces the risk for future hepatic decompensation or liver-related 
death.35 To maintain its benefit, treatment must be provided for long periods, often 
indefinitely.36  
Chronic HBV is determined by the presence of HBsAg or HBV DNA.  HBsAg is a 
marker of HBV infection, appearing in serum 1-10 weeks after exposure to HBV (figure 
2.2).37 In acute infections HBsAg becomes undetectable after 4-6 months.38 Chronic infection 
is defined as the persistence of HBsAg for more than 6 months. Current immunoassays are 
very sensitive, so it is rare that during infection HBsAg levels are undetectable39. The 
presence of anti-HBs indicates recovery from HBV and provides lifelong immunity.38 Anti-
HBs is produced early in the course of infection; however, it is not routinely detected until 
HBsAg clears. Very rarely, there is a short window period during which neither HBsAg nor 
anti-HBs are detectable. Less rare (~10-25% of the time) is the situation where HBsAg 
positive individuals have anti-HBs detected at the same time. This occurs most commonly in 
chronically infected patients40 with low level antibodies directed against a different subtype 
of HBsAg than that present in HBV infected patients. 
HBeAg is a marker of HBV replication and infectivity, and is detectable a short time 
after the appearance of HBsAg (figure 2.2).38 HBeAg is associated with detectable HBV 
DNA replication and acute liver disease.38,41 Anti-HBe seroconversion occurs just before 
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anti-HBs seroconversion37 and is associated with the disappearance of HBV DNA and the 
resolution of liver disease.38 Anti-HBe can persist for years after acute infection and for 
decades in chronically infected patients.38 
Anti-HBc appears within one month of HBsAg37 and is detectable throughout the 
course of HBV infection (figure 2.2).38 It is the only marker of infection during the rare 
window period between the depletion of HBsAg and the appearance of anti-HBs.42 Anit-HBc 
is predominantly immunoglobulin M (IgM) class during acute infection; however, during 
recovery IgM anti-HBc declines while the titer of immunoglobulin G (IgG) anti-HBc rises. 
Therefore, detection of IgM anti-HBc is usually interpreted as an indication of acute HBV 
infection. On the other hand, approximately 20% of patients have detectable anti-HBc for up 
to two years after the acute phase of infection. This, combined with the fact that IgM anti-
HBc can be detected in chronically infected patients during HBV exacerbation, misdiagnosis 
of acute infection might occur for patients who are not previously known to have chronic 
infection.43 IgG anti-HBc persists in patients who recover from acute infection and in those 
who progress to chronic infection.38 
 
HIV and Hepatitis B Co-infection 
HBV is more prevalent in HIV-infected individuals than in HIV-uninfected 
individuals. Worldwide, an estimated 2-4 million people are HIV/HBV co-infected44, 
equating to 5-10% of all HIV-infected individuals. In the general US population the 
prevalence of HBV is less than one percent.45 However, in HIV-infected populations the 
prevalence is higher, ranging from 6% to 14%.2,5,46-48 The prevalence of chronic HBV 
infection among HBV-unvaccinated HIV-infected individuals in HIV care is approximately 
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7.6%, suggesting that at least 60,000 individuals in the US are HIV/HBV co-infected and 
enrolled in HIV care.48   
HIV’s and HBV’s mutual mode of transmission is a key reason that HBV is more 
prevalent in HIV-infected individuals compared to HIV-uninfected individuals.49 HBV may 
be acquired prior to, concurrent with or subsequent to HIV infection. Both IVDU and MSM 
are the main risk factors for HIV/HBV co-infection. Other risk factors include gender 
(HIV/HBV co-infection is more common in males than in females) 45,50, age (young adults 
are at the highest risk of HBV and HIV infection) 50,51 and having multiple sexual 
partners.44,51 Another reason HBV is more prevalent in HIV-infected individuals compared to 
HIV-uninfected individuals is that a higher proportion (10-40%) of HIV-infected adults who 
acquire HBV will progress from acute to chronic infection52-56 compared to HIV-uninfected 
individuals (<10%).57,58   
The prevalence of HIV/HBV co-infection varies geographically, primarily due to 
differences in the principal route of transmission.36,59 In highly endemic areas vertical, or 
perinatal, transmission dominates.60 In low endemic regions such as the US, transmission is 
predominantly horizontal.18,60   
In HIV/HBV co-infected individuals liver damage can be caused in several ways: 1). 
by the direct toxic effects of ART61-64; 2). by hepatotoxicity of ART causing treatment 
interruption, which allows for HBV reactivation; 3). by the rigorous immune reconstitution 
induced by ART, which aggravates HBV infection leading to liver deterioration2,61,65-67 and 
4). by the direct effects of HBV in the absence of ART. 
HIV/HBV co-infected individuals have a more complex and limited efficacy of anti-
HBV treatment options compared to HBV-infected individuals.36 Seven drugs have been 
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approved for the treatment of chronic HBV, including pegylated interferon α-2a, adefovir, 
entecavir, telivudine (LdT), 3TC, FTC and TDF. Of these, pegylated interferon α-2a and LdT 
have activity only against HBV.  3TC, FTC and TDF have activity against both HBV and 
HIV. ART, particularly initial ART, typically contains at least one HBV active agent (3TC) 
and since the introduction of TDF, ART frequently contains two active agents (TDF and FTC 
or 3TC). The optimal treatment regimen has not been defined, particularly for patients with 
chronic HBV who do not yet require anti-HIV therapy, because of limited data, the 
overlapping drug activity of both viruses and the development of both HIV and HBV 
resistance.30,68-72   
Treating HIV/HBV co-infected patients must be balanced between the likelihood of 
response to anti-HBV therapy, the need to treat HIV, the prevention of drug resistance and 
minimizing the risk of drug-induced hepatotoxicity. The ideal time for initiating ART in 
HIV-infected patients remains debated,73,74 although recent studies suggest initiating early 
may provide clinical benefit.75 How to modify treatment approaches in the presence of HBV 
co-infection remains poorly studied. Currently the International AIDS Society recommends 
that for HIV/HBV co-infected patients, treatment for HIV should be considered at any CD4 
cell count.75 The US Department of Health and Human Services recommends treating HBV 
with pegylated interferon-alpha when treatment for HIV is not desirable.76 
HIV has a deleterious effect on HBV outcomes.  Studies conducted in the pre-ART era 
suggested that there was no negative effect of HIV on HBV outcomes.49,52,77-79 Another early 
study suggested that the progression to liver disease is actually decreased in the presence of 
HIV.80 However, more recent studies have shown that cirrhosis develops more quickly in 
HIV/HBV co-infected individuals than in HBV-infected individuals.28,81,82 Once cirrhosis 
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develops, hepatic decompensation and evolution to end stage liver disease is increased in 
HIV/HBV co-infected individuals compared to HBV-infected individuals.28,81,83 HIV/HBV 
co-infection also leads to an increase in the proportion of deaths due to liver-related disease 
2,47
, an increase in the rate of HBV infectivity49,81,84, an increase in the rate of HBV 
reactivation 7 and a higher rate of chronic hepatitis.52,77,85 
Co-infection with HCV, hepatitis D (HDV) or multiple HBV/HCV/HDV infection 
worsens outcomes.  HCV and HDV are common co-infectors of patients with HIV/HBV co-
infection. HDV can result in the most severe form of chronic viral hepatitis86 and co-
infection with HIV accelerates progression of delta-associated liver disease.86,87 The 
prevalence of multiple viral hepatitis (HBV/HCV, HBV/HDV, HCV/HBV/HDV) in HIV-
infected individuals is low (<3%); however, the prevalence is much higher than in the 
general population.88 HIV-infected patients dually infected with HBV and HCV have an 
accelerated progression to liver disease compared to HIV-infected patients89 and are more 
likely to develop hepatocellular carcinoma.90 Liver related mortality is also increased in this 
population compared to HIV-infected patients co-infected with HBV alone.91 
The impact of HBV on the progression of HIV remains debated. Several studies have 
found no impact of HBV co-infection on immunological and virological responses to 
ART.47,53,62,92-96 However, other studies have found an effect of HBV co-infection on CD4 
cell count and HIV RNA viral load. In a study of out-patients with chronic HBV, a higher 
rate of virologic failure was seen after initiation of ART in HIV-infected individuals 
compared to non-HIV infected individuals97, possibly due to the higher incidence of hepatitis 
resulting in a higher rate of HIV treatment interruption. Another study found that HIV/HBV 
co-infected individuals delayed CD4 cell count recovery at week four after initiating ART 
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compared to HIV-infected individuals; however, this effect was no longer present at week 
48.98   
Research has found an increased risk of all-cause mortality among HIV/HBV co-
infected individuals.46,47,92,93,97,99 At the same time, many studies have found no 
association.47,53,62,100,101 All of these studies occurred after the ART era began in 1997. Only a 
few studies have been reported in the United States2,91,96,99-101, three of which were limited to 
homosexual men 2,99,100 and another that was limited to veterans.101 The remaining two 
studies were performed in HIV clinics; however, both studies were small. Bonocini et al. 
looked at HBV-related and HIV-related deaths and concluded that while co-infection with 
HBV increased liver-related mortality, it had no effect on HIV-related mortality.91 
Scharschmidt et al. found a significant effect of HBV on all-cause mortality.96 This large 
effect could not be explained by liver-related deaths alone. Determining the causes of death 
amongst this important population is a topic deserving more attention. 
 
Summary 
In summary, the widespread use of ART has substantially decreased HIV-related 
morbidity and mortality1, and non-AIDS events, including liver-related complications are of 
increasing concern to HIV clinical care.2-5 Identifying HIV-infected patients who are at risk 
of HBV co-infection is important in order to target screening and prevention measures. Until 
the cohort of children who began routinely receiving HBV vaccine ages up, vaccinating high-
risk individuals remains clinically relevant for patient management and essential for the 
improvement of HIV care. Therefore, in this project we identified predictors of HIV/HBV 
co-infection. 
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It is unclear whether HIV/HBV co-infected individuals have inferior outcomes 
compared to HIV mono-infected individuals. As such, we assessed the effect of HBV co-
infection on all-cause mortality. Further, optimal treatment regimens for HIV/HBV co-
infected patients remain debated. Answering this question is necessary to inform the care and 
management of HIV/HBV co-infected patients. Consequently, we also examined whether, 
and to what extent, TDF affects response to initial ART, specifically HIV virologic and 
immunologic responses. 
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FIGURE 2.1. Incidence of acute hepatitis B virus, United States 
 
 
Source: http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview 
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FIGURE 2.2. Serologic pattern of hepatitis B virus 
 
 
 
Source: Specter Viral Hepatitis 1999 
  
 
 
CHAPTER THREE: DESCRIPTION OF DATA SOURCE 
 
For this project we relied on available data from the CNICS. CNICS is a collaboration 
of observational clinical cohorts. 
The CNICS study collects electronic medical records from eight sites across the United 
States (figure 3.1). Patients in the CNICS project are aged 18 years or older and initiated 
primary care at CNICS sites after January 1, 1995. The CNICS cohort population is diverse 
with respect to geographic distribution, age, sex, race/ethnicity and HIV transmission risk 
factor (table 3.1).  As of September 2008 nearly 20% of patients in the combined cohort are 
female. Thirty-five percent are Black, 11% are Hispanic and 49% are White. The majority of 
patients are between the age of 30 and 49 (63%). MSM is the risk factor of greatest 
prevalence (46%), followed by heterosexual contact (20%) and combined MSM-IVDU 
(13%).  
Approximately 1,400 new patients are added to the CNICS data each year and 10% 
leave care annually.  The median follow-up time is 33 months.  The majority of patients have 
been under care during the ART era. 
Data, which are subject to rigorous standards for site data quality prior to data 
transmission, are uploaded directly from CNICS site electronic medical record (EMR) 
systems and are checked for adherence to the established standards for terminology, format, 
data verification and quality assurance.  Site data quality control includes procedures specific 
for each data type: 1). Laboratory data are uploaded directly from Clinical Laboratory 
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Systems, and surveillance for coding changes and outliers is conducted; 2). Diagnoses 
are recorded prospectively in the EMR by the treating clinician and verified through 
systematic review of clinician progress notes and other medical records, event driven audits, 
and verification of random samples of events; 3). Medication data are entered by clinicians or 
prescription fill/refill data are uploaded directly from institutional pharmacy dispensing 
systems and verified through record review; 4). Each CNICS site maintains a death registry 
and queries the US Social Security Administration database and/or the National Death Index 
to confirm mortality data at least annually.102,103 In addition to querying administrative death 
registries, CNICS sites also employ active surveillance for deaths.  The Data Management 
Core group oversees the quality assurance process. 
We included all patients enrolled in one of the eight CFARs that feed data into CNICS 
who met the inclusion criteria.  Our inclusion criteria were: 
1. Documentation of HIV infection.  (Only HIV-infected individuals are enrolled.) 
2. At least 18 years of age. 
3. Results from at least one HBsAg or HBV DNA test. 
4. Initiated ART with no prior exposure to antiretroviral therapy.  
All CNICS participants provide written informed consent. Our study was approved by 
the University of North Carolina at Chapel Hill Institutional Review Board. All analyses 
were conducted in SAS® (version 9.1.3, SAS Institute, Inc., Cary, NC). 
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TABLE 3.1. Distribution of 15,792 patients included in the Centers for AIDS Research 
Network of Integrated Clinical Systems, as of September 2008 
   
Characteristic N  (%) 
   
   Site   
     Case Western Reserve University 1524  (9.7) 
     Fenway Community Health Center of Harvard University 1380  (8.7) 
     University of Alabama, Birmingham 2315  (14.7) 
     University of California, San Diego 3151  (20.0) 
     University of California, San Francisco 2390  (15.1) 
     University of Washington 2497  (15.8) 
     Johns Hopkins University 2535  (16.1) 
   
Age   
     < 18 15  (0.1) 
     18-19 68  (0.4) 
     20-29 2350  (14.9) 
     30-39 6525  (41.3) 
     40-49 5073  (32.1) 
     50-59 1495  (9.5) 
     60-69 225  (1.4) 
     =70 41  (0.3) 
   
Sex   
     Female 2907  (18.4) 
     Male 12883  (81.6) 
   
Race/Ethnicity   
     Black 5456  (34.5) 
     Hispanic 1711  (10.8) 
     White 7794  (49.4) 
     Other 831  (5.3) 
   
HIV Risk Factor   
     MSM* 7310  (46.3) 
     IVDU* 1018  (6.4) 
     MSM-IVDU 1993 (12.6) 
     Other 366  (2.3) 
     Unknown 1934  (12.2) 
   
   * MSM=men who have sex with men; IVDU=intravenous drug user  
Note: This table does not include the University of North Carolina, Chapel Hill. 
Source: http://www.uab.edu/cnics/ 
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FIGURE 3.1. Centers for AIDS Research Network of Integrated Clinical Systems sites 
 
Source: http://www.uab.edu/cnics/cnics-sites 
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CHAPTER FOUR: METHODS 
 
Specific Aim 1 
Among ART-naïve HIV-infected individuals, assess the impact of HBV co-infection 
on time to mortality. 
a. Compare demographic and clinical characteristics by HBV co-infection status. 
b. Determine differences in time to mortality by HBV co-infection status stratified by 
calendar interval of therapy initiation.  
 
Study Design Overview 
To determine the impact of HBV on time to mortality among HIV-infected individuals 
we conducted a retrospective cohort study using data collected as part of the CNICS cohort 
study. The CNICS cohort study is an optimal population within which to study HIV/HBV co-
infection as it is one of the largest HIV cohorts available and includes patients who have risk 
factors for HBV co-infection. The CNICS cohort also includes patients who initiated ART 
before and after modern therapy with efficacy against both HIV and HBV became available. 
We hypothesized that HBV co-infection was associated with a greater risk of death, but that 
this risk decreased over calendar time with the introduction of more potent HIV and HBV 
therapy. Our study was ruled as exempt by the UNC Institutional Review Board. 
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Study Population 
The study population included patients enrolled in the CNICS cohort study who 
initiated ART between 01 January 1998 and 30 June 2008.  CNICS captures comprehensive 
longitudinal demographic and clinical data from eight HIV treatment centers in the US. The 
CNICS study and data collection procedures have been previously described.104  
 
Inclusion Criteria 
Our study included all consenting antiretroviral-naïve HIV-infected persons who 
presented to one of the eight HIV treatment centers included in CNICS. Additional inclusion 
criteria were that the patient had to be at least 18 years of age, had to initiate ART with at 
least three antiretroviral agents [one of which could not be a nucleoside(tide) reverse 
transcriptase inhibitor (NRTI)] between 01 January 1998 and 30 June 2008, and had to have 
at least one HBsAg or HBV DNA result prior to ART initiation to be included. 
 
Data Management 
Sample size: The sample size was fixed so we calculated the power available to detect a 
clinically relevant hazard ratio. We expected a minimum of 5,000 HIV-infected treatment 
naïve patients initiating ART who had at least one HBsAg or HBV DNA serology result. We 
assumed an HBV prevalence of 10% and a two-sided alpha of 0.05. We varied the proportion 
of the cohort who died from 3% to 15% (figure 4.1).105,106 Under these conditions, with an 
expected mortality rate of 6% during follow-up, the power to detect a hazard ratio of 1.3 or 
greater was over 80%.  
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Approach to missing data: All patients in the CNICS cohort had data available to measure 
against our study inclusion criteria except 279 (6%) patients who did not have any HBsAg or 
HBV DNA results prior to ART initiation. Of the 4,427 patients who had available data and 
met the inclusion criteria for specific aim #1, 374 (9%) did not have any HCV antibody 
results. All other covariables had complete data. Because our data were largely complete, we 
performed a complete case analysis where we excluded patients who had missing 
information for HCV.  
 
Measurements and Analysis Plan – Specific Aim 1a 
Specific Aim 1a: Compare demographic and clinical characteristics by HBV co-infection 
status among ART-naïve HIV-infected individuals. 
 
Measurements 
Outcome: HBV co-infection was defined as a positive HBsAg or HBV DNA result prior to 
beginning ART. 
Additional covariables: Additional patient data included demographic and clinical 
characteristics. 
- Age at therapy initiation was calculated as the number of years between patients’ date of 
birth and date of ART start. For frequencies by calendar interval and HBV status, age was a 
continuous variable presented as median and interquartile range (IQR). For additional 
analyses, age was categorized into a dichotomous variable (≤40 years, > 40 years). 
- Sex and MSM combined patients’ sex at birth and MSM status into a three-level categorical 
variable (male MSM, male non-MSM and female). 
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-Race /ethnicity was categorized into a dichotomous variable (white, non-white). 
-History of IVDU was a dichotomous variable (yes, no). 
-Year of ART initiation was categorized into three intervals (1998-2001, 2002-2004 and 
2005-2008). 
- Type of initial ART was categorized into protease inhibitor (PI), ritonavir-boosted PI (PI/r), 
non-nucleoside reverse-transcriptase inhibitor (NNRTI) and Other, based on the ART 
regimen backbone agent. 
-Presence of an AIDS defining clinical condition at time of ART initiation was a 
dichotomous variable (yes, no). 
-HCV co-infection at time of ART initiation was a dichotomous variable (yes, no), based on 
whether the patient had a positive HCV antibody result. 
-APRI score is a non-invasive method for assessing liver fibrosis.107-109 It was calculated 
using Wai’s formula: (AST/upper limit of normal considered as 40 IU/L)/platelet count 
(expressed as platelets x 109/L) x 100.110 
-CD4 cell count (cells/mm3) was a continuous measure presented as median and IQR by 
calendar interval and HBV status. For additional analyses, CD4 cell count was categorized 
into a dichotomous variable based on distribution and association with the factor of interest. 
-HIV RNA level (log10 copies/mL) was a continuous measure presented as median and IQR 
by calendar interval and HBV status, and categorized as appropriate based on distribution 
and association with the factor of interest. For all analyses we considered an HIV RNA <400 
copies/mL as undetectable since viral load assays varied over time and sites. As needed 
undetectable values were assigned one-half the limit of detection (i.e., 200 copies/mL) for 
analyses. 
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-Creatinine level (mg/dL) was a continuous measure presented as median and IQR by 
calendar interval and HBV status, and categorized as needed and appropriate. 
-CNICS site is a categorical variable (Case Western Reserve University; Fenway Community 
Health Center of Harvard University; University of Alabama, Birmingham; University of 
California, San Diego; University of California, San Francisco; University of Washington; 
Johns Hopkins University; University of North Carolina, Chapel Hill).  
 
Data Analysis 
Descriptive analysis: We presented the number and percent of patients overall and stratified 
by HBV co-infection status as appropriate. We also presented the number and percent of 
patients overall and stratified by the calendar interval in which the patient initiated ART. 
Demographic and clinical characteristics were compared between patients with HIV/HBV 
co-infection and those with HIV mono-infection using Pearson’s chi-square test for 
categorical variables, Student’s t-test for normally distributed continuous variables and 
Wilcoxon’s rank sum test for non-normally distributed continuous variables.111 Covariables 
were compared between the three calendar intervals during which patients began ART using 
standard bivariable tests. All tests for assessing statistical significance were two-sided with 
α=0.05. 
Predictive analysis: Independent associations of having HBV co-infection were assessed 
using multivariable log-linear binomial regression. Risk ratios and 95% confidence intervals 
were calculated for each factor of interest. The equation for the log-linear binomial model 
can be expressed as: 
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where D is the outcome of interest and X1…Xn are the potential predictors. The interpretation 
of eβi for the log-linear binomial model is the risk ratio comparing those with Xi=1 to those 
with Xi=0 (referent), holding all other covariables constant. 
We first examined the individual bivariable relationships between each variable and the 
outcome. Covariables were included in the full model if the p-value from the corresponding 
bivariable analysis was less than 0.2. We then used backwards elimination, removing 
covariables from the model in order of p-value magnitude, to arrive at the final predictive 
model based on a p-value of less than 0.05.  
 
Measurements and Analysis Plan – Specific Aim 1b 
Specific Aim 1b: Among ART-naïve HIV-infected individuals, determine differences in time 
to mortality by HBV co-infection status stratified by calendar interval of therapy initiation.  
 
Measurements 
Outcome: Time to all-cause mortality was calculated as the number of days between patients’ 
ART start date and their date of death. 
Exposure: HBV co-infection was defined as a positive HBsAg or HBV DNA result prior to 
beginning ART. 
Additional covariables: Additional patient data included demographic and clinical 
characteristics as for specific aim 1a, except for age, CD4 cell count, log10 HIV RNA level 
and creatinine level at the time of ART initiation. These continuous variables were coded 
using splines with four equal knots based on the case distribution.112 
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Data Analysis 
Follow-up time was calculated as the number of days between ART initiation and the 
first of death from any cause, administrative censoring (at the first of two years following 
ART initiation or December 31, 2008), or attrition. Attrition was defined as the absence of a 
CD4 cell count or HIV RNA measure for more than 18 months (with the censor date equal to 
18 months after the last available result). We employed an intention to continue treatment 
approach where patients were assumed to have remained on their initial ART for the duration 
of follow-up.  
The Kaplan-Meier method and log-rank test were used to assess time to mortality by 
HBV co-infection status for the entire study period and for patients initiating ART during 
each of the calendar time intervals. Multivariable models were fit using Cox proportional 
hazards regression, which is based on the number of events per interval of time and models 
the hazard rate. While comparable to incidence rates, hazard rates are conditional on 
“survival” in the immediately preceding time interval. The proportional hazards model is 
expressed as: 
 
Where X=X1, X2,…Xn is a vector of explanatory variables, H0(tij) is the baseline hazard when 
X=0 and H(tij) is the hazard when X=x. When Xi is a binary predictor variable, the 
interpretation of eβi is the hazard ratio comparing those with Xi=1 to those with Xi=0 
(referent) at all times , adjusted for all other explanatory variables in the model.  
An assumption of the proportional hazards model is that the hazard ratio in the model 
is assumed to be constant, or proportional, across time.113 We evaluated the proportional 
hazards assumption using likelihood ratio test results comparing models with and without a 
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time interaction term and by examining plots of the log of the cumulative hazards by time. If 
necessary, the proportional hazards assumption was relaxed by adding categorical or 
continuous time interactions. Goodness of fit was assessed using deviance residuals and 
influence statistics. 95% confidence limits were used as a measure of precision. 
We evaluated effect measure modification (EMM) and confounding for HBV co-
infection. We then constructed a single, fully adjusted model with the main exposure and all 
relevant interaction terms and confounders. 
Assessment of Effect Measure Modification: We identified effect measure modifiers by 
considering the exposure-outcome relationship at each level of a third variable (the potential 
effect measure modifier) by including a product interaction term between the exposure and 
the potential effect measure modifier.114 EMM was examined only for variables for which 
stratified estimate would be qualitatively meaningful. We used a p-value of α=0.10 from the 
likelihood ratio test to indicate heterogeneity in the stratum-specific measures of 
association.115 Covariables found to be important effect measure modifiers were included in 
the multivariable model through an interaction term with the main exposure variable.  
Assessment of Confounding: Potential confounders were identified through the existing 
literature and directed acyclic graph analysis (figure 4.2).116,117 Covariables that were not 
found to be effect measure modifiers and that led to a change in the unadjusted effect 
estimate by more than 10% according to the formula  	
  
	
  
   were 
considered confounders and were included in the multivariable model.118 
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Specific Aim 2 
Among ART-naïve HIV/HBV co-infected individuals, assess response to ART by TDF 
receipt. 
a. Compare demographic and clinical characteristics by TDF receipt.  
b.  Evaluate HIV virologic response to ART by TDF status. 
c. Evaluate HIV immunologic response to ART by TDF status. 
 
Study Population 
The study population was a subset of the study population in specific aim 1, including 
those patients who were HIV/HBV co-infected at ART initiation.  
  
Inclusion Criteria 
The inclusion criteria were the same as for specific aim 1 with the addition of requiring 
a positive HBsAg or HBV DNA result prior to therapy initiation.  
 
Data Management 
Sample size: The sample size was fixed so we calculated the power available to detect a 
clinically relevant hazard ratio. As for specific aim 1, we expected a minimum of 5,000 HIV-
infected treatment naïve patients initiating ART who had at least one HBsAg or HBV DNA 
serology result. We assumed an HBV prevalence of 10% and a two-sided alpha of 0.05. We 
varied the expected proportion of the cohort with virologic failure from 10% to 30% (figure 
4.3).105,106 Under these conditions, with an expected event rate of 20% during follow-up, the 
power to detect a hazard ratio of 1.4 or greater was over 80%. 
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Approach to missing data: Of the 226 patients who met the inclusion criteria for specific aim 
#2, six (3%) did not have data for assessing liver function and an additional eight (4%) did 
not have any HCV antibody results. All other covariables had complete data. Because our 
data were largely complete, we performed a complete case analysis where we excluded 
patients who had missing information for liver function or HCV.  
 
Measurements and Analysis Plan – Specific Aim 2a 
Specific Aim 2a: Among ART-naïve HIV/HBV co-infected individuals, compare 
demographic and clinical characteristics by TDF receipt. 
 
Measurements 
Outcome: Inclusion of TDF in initial ART. 
Additional covariables: Additional patient data included demographic and clinical 
characteristics as for specific aim 1a. 
 
Data Analysis 
Descriptive analysis: We presented the number and percent of patients overall and in each 
covariable category stratified by TDF status. As for specific aim 1a, covariables were 
compared between patients who did and did not receive TDF using Pearson’s chi-square test 
to compare proportions of categorical variables, Student’s t-test to compare normally 
distributed continuous variables and Wilcoxon’s rank sum test to compare non-normally 
distributed continuous variables.111 All tests for assessing statistical significance were two-
sided with α=0.05. 
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Predictive analysis: Independent predictors of TDF use were assessed using multivariable 
log-linear binomial regression as described for specific aim 1a.  
 
Measurements and Analysis Plan – Specific Aim 2b 
Specific Aim 2b: Among ART-naïve HIV/HBV co-infected individuals, evaluate HIV 
virologic response to ART by TDF status. 
 
Measurements 
Outcome: Time to HIV virologic failure was defined as time to the first of two successive 
HIV RNA values >400 copies/mL after 16-weeks of ART exposure.119,120 
Exposure: Inclusion of TDF in initial ART, either alone or in combination with 3TC or FTC. 
Additional covariables: Additional patient data included demographic and clinical 
characteristics as for specific aim 1b. 
 
Data Analysis 
Analyses were the same as for specific aim 1b with two exceptions. First, follow-up 
time started at 16-weeks post ART initiation. In order to give patients an opportunity to 
respond to initial ART, patients were not eligible to experience the virologic failure outcome 
until after this 16-week interval. Second, where the proportional hazards assumption was not 
met, the time following ART initiation was stratified at the point where the curves from the 
log of the cumulative hazards plot were no longer parallel. We confirmed the cut point by 
visually examining the plot of hazard ratios over time and by verifying the proportional 
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hazards assumption was met on both sides of the cut point.121 All analyses were then 
performed for time included on either side of the cut point. 
 
Measurements and Analysis Plan – Specific Aim 2c 
Specific Aim 2c: Among ART-naïve HIV/HBV co-infected individuals, evaluate HIV 
immunologic response to ART by TDF status. 
 
Measurements 
Outcome: CD4 cell count response. 
Exposure: Inclusion of TDF in initial ART, either alone or in combination with 3TC or FTC. 
Additional covariables: Additional patient data included demographic and clinical 
characteristics as for specific aim 1b. 
 
Data Analysis 
CD4 cell counts were measured at 6-monthly intervals following ART initiation. We 
employed an intention to treat approach where patients were assumed to have remained on 
their initial ART for the duration of follow-up.  
 We used multivariable linear regression fit with generalized estimating equations to 
estimate the association between TDF use and CD4 count response. We used an independent 
correlation structure and robust standard errors to account for repeat CD4 count measures. 
The linear regression model is expressed as: 
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where  is the outcome of interest (CD4 count) and X1…Xn are the potential predictors. The 
interpretation of βi for the linear model is the average difference in CD4 count across time 
comparing those with Xi=1 to those with Xi=0 (referent), holding all other covariables 
constant. 
EMM and confounding (figure 4.4) were evaluated as for specific aim 1b. 
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FIGURE 4.1. Power curves for specific aim 1 varying the proportion of the cohort who died 
between 3% and 15% 
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FIGURE 4.2. Directed acyclic graph showing the relationship between HBV co-infection 
and time to all-cause mortality for specific aim #1 
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FIGURE 4.3. Power estimates for specific aim 2 varying the proportion of the cohort with 
virologic failure between 10% and 30% 
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FIGURE 4.4. Directed acyclic graph showing the relationship between tenofovir disoproxil 
fumerate status and HIV virologic failure for specific aim #2 
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CHAPTER FIVE: RECENT IMPROVEMENTS IN SHORT-TERM MORTALITY 
AMONG HIV AND HBV CO-INFECTED PATIENTS, 1998-2008 CNICS COHORT 
STUDY 
 
Introduction 
As antiretroviral therapy (ART) has reduced mortality from HIV, the proportion of 
deaths with liver-related causes has risen.122,123 HIV and hepatitis B virus (HBV) co-infected 
patients are more likely than HBV-uninfected patients to experience liver-related mortality, 
with HBV co-infection possibly accounting for some of the increase in the proportion of 
deaths with liver-related causes among HIV-infected individuals.47  
Tenofovir (TDF), emtricitabine (FTC) and lamivudine (3TC) are antiretroviral (ARV) 
agents with activity against both HIV and HBV. Combination TDF with either FTC or 3TC 
is effective for controlling HBV DNA among HIV-infected patients.124,125 TDF was approved 
for use in 2001, and by 2006, US treatment guidelines recommended TDF and 3TC/FTC as 
preferred agents for treating co-infected patients.126 At present, these drugs are not widely 
used in resource limited settings where HBV is more prevalent and HIV/HBV co-infection 
more common than in the US.127 
The relationship between HBV co-infection and mortality has not been evaluated in 
patients treated with antiretroviral therapy since the introduction of antiviral agents that have 
activity against both HIV and HBV.  In this study, we assessed the effect of HBV co-
infection on all-cause mortality among HIV-infected patients from 1998 to 2008 in a large 
multisite clinical cohort in the United States, the Centers for AIDS Research Network of 
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Integrated Clinical Systems (CNICS). We hypothesized that HBV co-infection is associated 
with a greater risk of death, but that this risk decreased with the introduction of more potent 
HIV and HBV therapy.  
 
Methods 
Study population 
The study population included patients enrolled in CNICS, a large multisite HIV 
clinical cohort study in the US. CNICS captures comprehensive longitudinal demographic 
and clinical data from eight HIV treatment centers.  The CNICS study and data collection 
procedures have been previously described.104 For these analyses we included all 
antiretroviral-naïve patients who initiated ART with at least three antiretroviral agents [one 
of which could not be a nucleoside(tide) reverse transcriptase inhibitor (NRTI)] between 
January 1, 1998 and June 30, 2008. Patients also had to have at least one hepatitis B surface 
antigen (HBsAG) or HBV DNA result prior to ART initiation to be included (n=98 were 
excluded because an HBV result was not available pre-ART initiation). Each CNICS site 
receives local Institutional Review Board approval, and this study was approved by the 
University of North Carolina at Chapel Hill Institutional Review Board.   
 
Measures 
HBV co-infection was defined as a positive HBsAg or HBV DNA result prior to 
beginning ART.  Mortality included deaths from any cause and was determined by local 
CNICS site death searches as well as regular queries to the US Social Security Death Index. 
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Calendar time was divided into three time intervals to align with the introduction and uptake 
of TDF and FTC: 1998-2001; 2002-2004; and 2005-2008.  
Patient demographic characteristics considered as affecting the relationship between 
HIV/HBV co-infection and mortality were age, sex, race/ethnicity, HIV risk transmission 
group [including men who have sex with men (MSM) and intravenous drug use (IVDU)] and 
CNICS site. Clinical factors were measured at ART initiation and included year of ART 
initiation, initial ART regimen anchor drug [non-nucleoside reverse-transcriptase inhibitor 
(NNRTI), protease inhibitor (PI) or ritonavir-boosted PI], AIDS defining clinical condition, 
hepatitis C virus (HCV) co-infection status, HIV RNA level, CD4 cell count and creatinine 
level.  
 
Statistical Analysis 
Follow-up time started at ART initiation and ended at the first of death from any cause, 
administrative censoring (at the first of two years following ART initiation or December 31, 
2008), or attrition. We administratively censored follow-up at two years following ART 
initiation to ensure adequate sample size for making inferences in both groups of patients 
(HBV-infected and HBV-uninfected). Attrition was defined as the absence of a CD4 cell 
count or HIV RNA measure for more than 18 months (with the censor date equal to 18 
months after the last available result). Clinical and demographic characteristics were 
compared across calendar time intervals and by HBV co-infection status with Pearson’s chi-
square test, Student’s t-test, Wilcoxon’s rank sum test and one-way analysis of variance, as 
appropriate. Factors associated with HBV co-infection at ART initiation were assessed using 
multivariable log-linear binomial regression. For all analyses we used an intention to treat 
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approach where patients were assumed to have remained on their initial ART for the duration 
of follow-up.    
The Kaplan-Meier method and log-rank test were used to assess time to mortality by 
HBV co-infection status for the entire study period and for patients initiating ART during 
each of the calendar time intervals. Multivariable models were fit using Cox proportional 
hazards regression.  The proportional hazards assumption was assessed using likelihood ratio 
test results comparing models with and without a time interaction term and by examining 
plots of the log of the cumulative hazards by time. Confounders were selected based on the 
existing literature, use of causal diagrams and change-in-estimate calculations.117,118 All tests 
for assessing statistical significance were 2-sided with α=0.05. All analyses were performed 
using SAS version 9.2 (SAS Institute Inc., Cary, NC).  
 
Results 
Study Population 
Of the 3,706 patients included in this study 21% were women, 48% were White, 40% 
were Black and 12% were of other races/ethnicities.  Patients’ median age at therapy 
initiation was 39 years (interquartile range [IQR]: 33, 45). The median year of ART initiation 
was 2004 (IQR: 2001, 2006). Eighteen percent of patients had a history of IVDU and 53% 
were MSM (66% of all men). The first ART included an NNRTI (56%), PI (21%), ritonavir-
boosted PI (22%) and other agents (<1%). At ART initiation 28% of patients had an AIDS 
defining clinical condition and 15% were HCV co-infected. The median pre-ART CD4 cell 
count and HIV RNA levels were 176 cells/mm3 (IQR: 47, 293) and 4.93 log10 copies/mL 
 40 
 
(IQR: 4.44, 5.46) respectively. The median creatinine level was 0.90 mg/dL (IQR: 0.80, 
1.00).  
The number of patients initiating ART in each of the three calendar periods, 1998-
2001, 2002-2004 and 2005-2008, was 954 (26%), 1,063 (29%) and 1,689 (46%) respectively.  
Differences across calendar time were seen for several patient characteristics (Table 1). Sex 
and MSM varied slightly across calendar time (P <0.001). The proportion of patients with a 
history of IVDU decreased over the study period from 23% to 16% (P <0.001). Ritonavir-
boosted PIs were used most frequently during 2002-2004 and non-boosted PIs were used less 
frequently in more recent calendar years (P <0.001). The proportion of patients with HCV 
co-infection decreased from 20% to 13% (P <0.001). The median CD4 cell count at the time 
of ART initiation increased while the proportion of patients with an AIDS defining clinical 
condition decreased (both P <0.001). The median HIV RNA level decreased from 5.00 log10 
copies/ml (IQR: 4.47, 5.55) to 4.88 log10 copies/ml (IQR: 4.35, 5.37) (P=0.001). No 
differences were seen across the three calendar periods for age, race/ethnicity, or creatinine 
level. 
 
Hepatitis B Co-infection 
Overall, 6% (n=212) of patients were HBV-infected at ART initiation, with prevalence 
stable from 1998-2008. HBV-infected patients were comparable to HBV-uninfected patients 
by most patient demographic and clinical characteristics at ART initiation (Table 2). 
However, HBV-infected patients were more likely to be men, both MSM and non-MSM (P 
<0.001), and to have a PI or NNRTI included in first ART (P=0.034). In multivariable 
analyses each of these factors remained associated with HBV infection (Table A.1). 
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Specifically, MSM and non-MSM men were over four and three times as likely to be HBV-
infected in comparison to women, respectively (Relative Risk [RR]=4.41, 95% Confidence 
Interval [CI]: 2.44, 7.96; and RR=3.26 95% CI: 1.77, 6.01 respectively). Patients whose first 
ART included ritonavir-boosted PI were less likely to be HBV-infected compared to those 
receiving either an NNRTI or a PI (RR=0.59, 95% CI: 0.41, 0.86).  
 
Antiretroviral Therapy Provision 
The overall distribution of anchor drugs included in initial ART was generally similar 
for HBV-infected and HBV-uninfected patients across calendar years, with the exception 
noted above that HIV/HBV co-infected patients were more likely to receive an NNRTI or PI 
across all years (Figure 1). After the introduction of NNRTIs and ritonavir-boosted PIs, the 
proportion of patients receiving each was generally stable across time, while the proportion 
of patients receiving a PI decreased over time.  
Among HIV/HBV co-infected patients initial therapy included TDF with FTC (n=106 ; 
50%), TDF with 3TC (n=23; 11%), TDF alone (n=2; 1%), 3TC alone (n=77; 36%), and FTC 
alone in a single patient (<1%). Three HBV-infected patients did not receive TDF, FTC or 
3TC as part of their first ART regimen. Among HBV-uninfected patients 1,449 (41%) 
received TDF with FTC, 296 (8%) received TDF with 3TC, 24 (1%) received TDF alone, 
1,567 (45%) received 3TC alone, and 27 (1%) received FTC alone. The remaining 121 HBV-
uninfected patients did not receive TDF, FTC or 3TC as part of their first ART regimen. 
Among the 2,120 patients, with and without HBV co-infection, who began therapy after 
2003, 78% had TDF with FTC or 3TC included in their initial therapy. This proportion 
increased to 84% among the 1,265 patients who began therapy after 2005. 
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Hepatitis B Co-infection Effect on Mortality 
Among the 3,706 patients in the study, 296 (8%) died during the two years of follow-
up from ART initiation. The proportion of HBV uninfected patients who died decreased 
slightly during the latest calendar interval of therapy initiation, with 5, 5 and 3% of patients 
beginning ART in 1998-2001, 2002-2004 and 2005-2008 dying within two years, 
respectively (Supplemental figure 1). This decrease was not statistically significant (log-rank 
p-value comparing 1998-2001 vs. 2005-2008 = 0.175). In contrast, the proportion of HBV 
infected patients who died decreased four-fold over the calendar intervals of therapy 
initiation. Among HBV co-infected patients who initiated ART during 1998-2001, 2002-
2004 and 2005-2008, 12, 10 and 3% died, respectively (log-rank p-value comparing 1998-
2001 vs. 2005-2008 = 0.057). 
Over the course of the study period, the difference in time to mortality comparing 
HBV-infected to uninfected patients diminished. During the 1998-2001 calendar interval of 
therapy initiation, HBV-infected patients had more than twice the hazard of death during 
their first two years on ART compared to HBV-uninfected patients (unadjusted HR=2.33, 
95% CI: 1.00, 5.45) (Table 3, Figure 2). This result was consistent after adjusting for 
confounders (adjusted HR=2.20, 95% CI: 0.92, 5.23). In later calendar intervals the hazard 
ratio decreased to 2.00 (95% CI: 0.85, 4.63) for patients initiating therapy during 2002-2004 
and to 0.95 (95% CI: 0.30, 3.05) for patients initiating therapy during 2005-2008. Further, 
adjusting for confounders did not appreciably change the estimates or their associated 
precision (adjusted HR=2.09, 95% CI: 0.86, 5.07 for patients initiating ART in 2002-2004; 
adjusted HR=0.96, 95% CI: 0.29, 3.16 for patients initiating ART in 2005-2008). 
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Discussion 
In this large national HIV clinical cohort we observed a consistent proportion of HIV-
infected patients initiating ART between 1998 and 2008 with HBV-infection at 6%. As 
expected, HBV-infected patients were more likely to be MSM44,48 and to have non-invasive 
testing consistent with fibrosis.128 In more recent calendar years patients were starting ART 
at higher CD4 cell counts and lower HIV RNA levels which has been documented by 
others.129 We observed reductions in short-term mortality following ART initiation in the 
most recent calendar years, consistent with other recent reports.130 We also observed a rapid 
uptake of new ARV agents as they became available. 
Our most notable result was a substantial decrease in more recent calendar years of 
early mortality following ART initiation among HBV-infected patients. HBV-infected 
patients who began ART between 1998 and 2001 were over twice as likely to die in the first 
two years following therapy initiation compared to HBV-uninfected patients, but this 
difference disappeared in more recent calendar years, with no difference in time to death by 
HBV infection status among patients starting ART between 2005 and 2008. These findings 
suggest that during the first two years following ART initiation, HBV-infection may no 
longer increase the risk of all-cause death among HIV-infected individuals. 
The reduction in early mortality among HBV-infected patients remained after 
adjustment for patient demographic and clinical characteristics at ART initiation, including 
sex and MSM, IVDU, type of initial ART, AIDS defining clinical condition, HCV infection, 
CD4 cell count, and HIV RNA level. These results suggest that the changes in mortality are 
not explained by changes in the patient population across calendar time intervals. A possible 
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reason for the decrease was the rapid and widespread uptake of combination TDF with 3TC 
or FTC as part of initial ART. Unfortunately, we were unable to assess the extent to which 
these anti-HBV agents affected the reductions in mortality directly. Because nearly all HBV-
infected patients received TDF (with 3TC or FTC) as soon as it became available, resulting 
in lack of heterogeneity across calendar time, we were unable to make desirable 
comparisons. 
Others have shown that, among HIV/HBV co-infected individuals, provision of anti-
HBV agents including TDF with 3TC or FTC reduces HBV DNA levels and ongoing liver 
damage.131,132 Additionally, early reports suggest that HIV RNA levels may also be lower 
among HIV/HBV co-infected individuals treated with ART including TDF and 3TC or FTC 
than without these anti-HBV agents.125,133 Therefore it is likely that the use of these anti-HIV 
and HBV agents as part of ART reduces early mortality among HIV/HBV co-infected 
patients; however, whether this is the effect of better treatment of HBV, HIV or some 
combination thereof requires further study. 
Our results from the pre-2002 calendar years are consistent with those from studies that 
evaluated mortality among HIV/HBV co-infected patients during the late 1990s and early 
2000s. HIV/HBV co-infected patients included in the EuroSIDA study between 1997 and 
2004 were 50% more likely to die from all causes and over 200% more likely to die from 
liver-related causes compared to HBV-uninfected patients.47 HIV/HBV co-infected patients 
enrolled in the Multicenter AIDS Cohort Study who initiated therapy between 1996 and 2006 
were also at a higher risk of death compared to HBV-uninfected patients.134 To the best of 
our knowledge, our results are the first to isolate the effect of HIV/HBV co-infection on time 
to mortality following the widespread use of TDF with FTC or 3TC. 
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Our study has a number of strengths including generalizability to patients receiving 
clinical care in the United States. The CNICS clinical cohort is one of the largest clinical 
cohort studies and has a national distribution of study sites with a diverse patient population 
and demographic composition that is largely consistent with national figures.135 We were 
also able to include patients initiating ART over a long period of time spanning 1998 through 
2008, and captured the rapid uptake of ARVs efficacious for treatment of both HIV and 
HBV. 
However our study also has a number of limitations. We assessed all-cause mortality in 
these analyses and were unable to specifically consider liver-related mortality. Given the 
small sample size of HBV co-infected patients even in this large cohort, we were limited to 
assessing mortality over the first two years following ART initiation. Additional work on 
mortality by HBV status over longer follow-up time is needed. We were unable to account 
for time from HIV infection, but we did adjust for CD4 cell count as an indicator of HIV 
disease progression at ART initiation. We were also unable to account for time from HBV 
infection. As with all observational studies our results may also be affected by residual 
unmeasured confounding. 
Additional work is indicated that considers response to agents with activity against 
both HIV and HBV (TDF, FTC and 3TC), including HBV DNA and HIV RNA suppression, 
immunologic response, liver disease progression, other liver and non-liver related incident 
morbidity and mortality, especially over longer periods of time. Though our results suggest 
that short term mortality is comparable by HBV status among patients receiving modern 
ART, it is unclear whether this is sustainable over the lifespan of co-infected patients, 
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particularly in the presence of resistance evolution.136-138 Therefore, ongoing efforts to 
identify other agents with activity against both HIV and HBV are indicated.  
Further, effective treatment is not a substitute for prevention. Despite the HBV vaccine 
being available in the US for nearly 30 years, a substantial proportion of high-risk individuals 
have not been immunized.139 Because HBV infection can occur before, after or concurrent 
with HIV infection, and because HBV vaccine-induced immunity is compromised in HIV-
infected patients140, it is vital that efforts continue to achieve wide-spread uptake of HBV 
vaccination through routine and other immunization opportunities.141,142    
The association between HBV infection and decreased time to mortality among HIV-
infected patients who began ART early in our study period disappeared for patients initiating 
ART in more recent calendar years. Because uptake of TDF with 3TC or FTC was rapid, it 
was not possible to measure the extent to which modern ART may have been responsible for 
the attenuated risk of HBV on time to all-cause mortality; however, we ruled out the 
contribution of several competing explanations. Our findings have implications for clinical 
care in the US and for strategies to best improve treatment for patients in resource limited 
settings where the burden of HIV/HBV co-infection is high 
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TABLE 5.1. Patient characteristics by calendar period of antiretroviral therapy initiation 
among 3706 HIV-infected patients, CFAR Network of Integrated Clinical Systems 1998-
2008 
        
 
   1998-2001     2002-2004    2005-2008  
        Characteristic N  (%) N  (%) N  (%) P 
        
        Total 954 1063 1689  
        
Age in years, median (IQR) 38 (33, 44) 39 (33, 45) 39 (32, 46)   0.120 
        
White race/ethnicity 429 (45) 503 (47) 835 (49)   0.084 
        
Sex and MSM        
     Male MSM 465 (49) 559 (53) 931 (48) <0.001 
     Male non-MSM 293 (31) 257 (24) 441 (26)  
     Female 196 (21) 247 (23) 317 (19)  
        
IVDU 215 (23) 180 (17) 263 (16) <0.001 
        
Type of initial ART        
     PI 327 (34) 167 (16) 278 (16) <0.001 
     PI/r 85 (9) 329 (31) 422 (25)  
     NNRTI 532 (56) 563 (53) 985 (58)  
     Other 10 (1) 4 (<1) 4 (<1)  
        
AIDS defining clinical condition 311 (33) 347 (33) 385 (23) <0.001 
        
HBV co-infection 52 (5) 62 (6) 98 (6)   0.917 
        
HCV co-infection 187 (20) 157 (15) 226 (13) <0.001 
        
CD4 cell count (cells/mm3), 
median (IQR) 130 (29, 294) 156 (39, 268) 211 (74, 303) <0.001 
        
HIV RNA level (log10 copies/ml), 
median (IQR) 5.00 (4.47, 5.55) 4.98 (4.55, 5.50) 4.88 (4.35, 5.37) 0.001 
        
Creatinine level (mg/dL), median 
(IQR) 0.90 (0.70, 1.00) 0.90 (0.80, 1.00) 0.90 (0.80, 1.09) 0.248 
        
        NOTES: IQR=inter-quartile range; MSM=men who have sex with men; IVDU=intravenous drug use; 
ART=antiretroviral therapy; PI=protease inhibitor, PI/r=ritonavir-boosted protease inhibitor; NNRTI=non-nucleoside 
revers-transcriptase inhibitor; Other=other antiretroviral agents including fusion and integrase inhibitors; 
HBV=hepatitis B virus; HCV=hepatitis C virus 
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TABLE 5.2. Patient characteristics by hepatitis B co-infection at antiretroviral therapy 
initiation among 3706 HIV-infected patients, CFAR Network of Integrated Clinical Systems 
1998-2008 
        
        
 HBV-uninfected  HBV-infected   
Characteristic N  (%)  N  (%)  P 
        
        Total 3494  212   
        
Age in years, median (IQR) 39 (33, 45)  39 (33, 44)    0.759 
        
White race/ethnicity 1669 (52)  98 (46)    0.663 
        
Sex and MSM        
     Male MSM 1814 (52)  141 (67)  <0.001 
     Male non-MSM 932 (27)  59 (28)   
     Female 748 (21)  12 (6 )   
        
IVDU 625 (18)  33 (16)    0.390 
        
Year of ART initiation        
     2005-2008 1591 (46)  98 (46)    0.917 
     2002-2004 1001 (29)  62 (29)   
     1998-2001 902 (26)  52 (24)   
             
Type of initial ART        
     PI 721 (21)  51 (24)    0.034 
     PI/r 804 (23)  32 (15)   
     NNRTI 1951 (56)  129 (61)   
     Other 18 (1)  0 (0.00)   
        
AIDS defining clinical condition 972 (28)  71 (33)    0.075 
        
HCV co-infection 541 (15)  29 (14)    0.480 
        
CD4 cell count (cells/mm3), 
median (IQR) 179 (49, 293) 
 128 (33, 294)    0.101 
        
HIV RNA level (log10 copies/ml), 
median (IQR) 4.93 (4.45, 5.46) 
 4.89 (4.38, 5.34)    0.194 
        
Creatinine level (mg/dL, median (IQR) 0.90 (0.80, 1.00)  0.90 (0.80, 1.00)    0.821 
        
        NOTES: IQR=inter-quartile range; MSM=men who have sex with men; IVDU=intravenous drug use; 
ART=antiretroviral therapy; PI=protease inhibitor, PI/r=ritonavir-boosted protease inhibitor; NNRTI=non-nucleoside 
revers-transcriptase inhibitor; Other=other antiretroviral agents including fusion and integrase inhibitors; 
HCV=hepatitis C virus 
 
 
 
. 
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TABLE 5.3. Effect of hepatitis B co-infection at antiretroviral therapy initiation on time to 
mortality stratified by year of therapy initiation among 3706 HIV patients, CFAR Network of 
Integrated Clinical Systems 1998-2008 
        
  HR (95% CI) [P-value]  
Year of ART initiation  Unadjusted  Adjusted†  
       
 
       
 1998-2001        
Hepatitis B            Yes  2.33 (1.00, 5.45) 0.051  2.39 (1.00, 5.70) 0.051 
 
                                                  No  1   1  
 
          
 
2002-2004       
 
Hepatitis B            Yes  2.00 (0.85, 4.63) 0.110  2.25 (0.94, 5.38) 0.069 
 
                                                  No  1   1  
 
          
 
2005-2008       
 
Hepatitis B            Yes  0.95 (0.30, 3.05) 0.935  1.00 (0.31, 3.27) 0.999 
 
                                                  No  1   1  
 
        
        † Models adjusted for age, race/ethnicity, sex, HIV exposure, initial antiretroviral therapy, AIDS defining clinical condition, 
hepatitis C co-infection, pre-therapy CD4 count, pre-therapy HIV RNA level, pre-therapy creatinine level and CNICS site. 
NOTES: Models fit with Cox proportional hazards regression; HR=hazard ratio; CI=confidence interval;   
ART=antiretroviral therapy 
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FIGURE 5.1. Initial antiretroviral therapy across calendar time among 3706 HIV-infected patients, CFAR Network of Integrated 
Clinical Systems 1998-2008 
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FIGURE 5.2. Time from antiretroviral therapy initiation to mortality among 3706 HIV-
infected patients who started therapy between 1998-2001, 2002-2005 and 2005-2008, 
stratified by hepatitis B co-infection status, CFAR Network of Integrated Clinical Systems  
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SUPPLEMENTAL TABLE 5.1. Patient characteristics by calendar period of antiretroviral therapy initiation and hepatitis B co-
infection status among 3706 HIV-infected patients, CFAR Network of Integrated Clinical Systems 1998-2008 
                
 HBV-uninfected  HBV-infected 
          
 1998-2001 2002-2004 2005-2008   1998-2001 2002-2004 2005-2008  
                Characteristic N  (%) N  (%) N  (%) P  N (%) N (%) N (%) P 
                
                Total 902 1001 1591   52 62 98  
                
Age in years, median (IQR) 39 (33, 44) 
39  
(33, 45) 
39 
(32, 46)   0.174 
 38 
(34, 43) 
39 
(33, 42) 
40 
(33, 45)   0.417 
                
White race/ethnicity 406 (45) 474 (47) 789 (50)   0.084  23 (44) 29 (47) 46 (47)   0.946 
                
Sex and MSM                
     Male MSM 434 (48) 516 (52) 864 (54)   0.001  31 (60) 43 (69) 67 (68)   0.573 
     Male non-MSM 274 (30) 241 (24) 417 (26)   19 (37) 16 (26) 24 (24)  
     Female 194 (22) 244 (24) 310 (19)   2 (4) 3 (5) 7 (7)  
                
IVDU 200 (22) 175 (17) 250 (16) <0.001  15 (29) 5 (8) 13 (13)   0.006 
                
Type of initial ART                
     PI 303 (34) 157 (16) 261 (16) <0.001  24 (46) 10 (16) 17 (17) <0.001 
     PI/r 83 (9) 315 (31) 406 (26)   2 (4) 14 (23) 16 (16)  
     NNRTI 506 (56) 525 (52) 920 (58)   26 (50) 38 (61) 65 (66)  
     Other 10 (1) 4 (0) 4 (0)   0 (0) 0 (0) 0 (0)  
                
AIDS defining clinical condition 293 (32) 323 (32) 356 (22) <0.001  18 (35) 24 (39) 29 (30)   0.483 
                
HCV co-infection 175 (19) 148 (15) 218 (14) <0.001  12 (23) 9 (15) 8 (8)   0.040 
                
CD4 cell count (cells/mm3), 
median (IQR) 
132 
(29, 294) 
157 
(39, 267) 
214 
(78, 303) <0.001 
 95 
(27, 276) 
133 
(46, 290) 
143 
(33, 307)   0.527 
                
HIV RNA level (log10 copies/ml), 
median (IQR) 
5.00 
(4.47, 5.56) 
5.00 
(4.58, 5.51) 
4.88 
(4.35, 5.38) <0.001 
 5.00 
(4.47, 5.46) 
4.87 
(4.38, 5.23) 
4.81 
(4.37, 5.24)   0.613 
                
Creatinine level (mg/dL), median 
(IQR) 
0.90 
(0.70, 1.00) 
0.90 
(0.80, 1.00) 
0.90 
(0.80, 1.08)   0.252 
 0.80 
(0.75, 0.90) 
0.90 
(0.80, 1.00) 
0.97 
(0.80, 1.09)   0.830 
                
                NOTES: IQR=inter-quartile range; MSM=men who have sex with men; IVDU=intravenous drug use; ART=antiretroviral therapy; PI=protease inhibitor, PI/r=ritonavir-
boosted protease inhibitor; NNRTI=non-nucleoside revers-transcriptase inhibitor; Other=other antiretroviral agents including fusion and integrase inhibitors; 
HBV=hepatitis B virus; HCV=hepatitis C virus 
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SUPPLEMENTAL FIGURE 5.1. Time from antiretroviral therapy initiation to mortality 
among 3494 HIV-infected patients and 212 HIV/HBV co-infected patients, stratified by year 
of therapy initiation, CFAR Network of Integrated Clinical Systems  
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CHAPTER SIX: TENOFOVIR DISOPROXIL FUMARATE FOR TREATMENT OF 
HIV AND HEPATITIS B CO-INFECTED PATIENTS – EFFECT ON HIV 
OUTCOMES 
 
Introduction 
The widespread use of modern ART has substantially decreased HIV-related morbidity 
and mortality.143 However, non-AIDS events, including liver-related complications, are of 
increasing concern in HIV clinical care.122,144 The prevalence of HBV in the general US 
population is <1%.45 Among HIV-infected patients HBV prevalence is 6-14%, due largely to 
mutual modes of transmission and shared risk factors.2,5,46,48 Additionally, 10-40% of HIV-
infected patients who acquire HBV progress from acute to chronic infection56 compared to 
<10% of HIV-uninfected individuals.44 Co-infection HBV can lead to substantial liver 
complications including cirrhosis and end stage liver disease.145  In one study of HBV-
infected men with and without HIV coinfection, HIV/HBV co-infected patients were 
approximately 19-times more likely to die from liver disease compared to those with HBV 
infection alone.2 Based on these and other data, HBV has been recognized as a significant 
cause of morbidity and mortality in HIV-infected patients.  
Three antiretroviral agents have activity against both HIV and HBV, 3TC, FTC and 
TDF. Current HIV treatment guidelines recommend that HIV/HBV co-infected individuals 
receive TDF with either 3TC or FTC, in addition to other agents.146 This recommendation is 
based on demonstrated TDF efficacy on HBV virologic response, HBV drug resistance, 
progression of HBV, renal safety and survival.125,132   
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Among HIV/HBV co-infected patients TDF improves HBV-related outcomes,125,132 but 
thorough evaluation of HIV outcomes would also inform clinical decisions. Therefore we 
used a large and representative US clinical cohort study to examine whether, and to what 
extent, TDF affects response to initial ART, specifically HIV RNA suppression and CD4 
count response.  
 
Methods 
Study Population 
CNICS is a large HIV clinical cohort that includes 8 clinical sites across the US.104 
CNICS collects comprehensive data on more than 20,000 HIV-infected adults who have 
received HIV care since 1995. For this study we included all antiretroviral-naïve patients 
who were HBV co-infected and initiated ART with at least three antiretroviral agents [one of 
which could not be a nucleoside(tide) reverse transcriptase inhibitor (NRTI)] between 1 
January 1998 and 30 June 2008. The study was approved by the University of North Carolina 
at Chapel Hill Institutional Review Board.   
 
Measures 
Patients with positive HBsAg or HBV DNA results prior to ART initiation were 
considered HBV co-infected. The primary exposure was inclusion of TDF in initial ART, 
either alone or in combination with 3TC or FTC.  HIV virologic failure was defined as 
having two successive HIV RNA values >400 copies/mL after 16-weeks of ART exposure, 
and the first date where HIV RNA was >400 copies/mL was used as the date of virologic 
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failure.119,120 Five patients whose last HIV RNA was >400 copies/mL with no confirmatory 
measure were considered to have virologic failure.  
Patient demographic and clinical characteristics at ART initiation considered as 
affecting treatment responses were age, sex, race/ethnicity, HIV risk transmission group 
[including MSM and IVDU], year of ART initiation, initial ART regimen anchor drug 
[NNRTI, PI or PI/r], AIDS defining clinical condition, HCV co-infection status, APRI score, 
HIV RNA level, CD4 count, creatinine level and CNICS site. APRI score is a non-invasive 
method for assessing liver fibrosis.107-109 It was calculated using Wai’s formula: (AST/upper 
limit of normal considered as 40 IU/L)/platelet count (expressed as platelets x 109/L) x 
100.110  
 
Statistical analysis 
For HIV virologic failure, follow-up time began at 16 weeks post-ART initiation. For 
CD4 count response, follow-up time began at ART initiation. Follow-up ended at the first of 
death from any cause, administrative censoring (December 31, 2008), or loss to follow-up. 
Loss to follow-up was defined as the absence of CD4 count or HIV RNA measures for more 
than 18 months (with the censor date equal to 18 months after the last available result). 
Clinical and demographic characteristics were contrasted by TDF use with Pearson’s chi-
square test, Student’s t-test and Wilcoxon’s rank sum test, as appropriate. Independent 
predictors of TDF use were assessed using multivariable log-linear binomial regression. 
Time to HIV virologic failure was evaluated among the 208 (98%) patients under 
observation at 16 weeks post-ART initiation. Patients were eligible to experience the 
virologic failure outcome following this 16-week interval. Of four patients excluded because 
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they did not complete 16 weeks of ART, three did not receive TDF in initial ART and each 
died at 2, 6 and 11 weeks following ART initiation; one patient received TDF and died 6 
weeks after initiating ART. All 212 patients were considered for CD4 count response. For all 
analyses we used an intention to treat approach where patients were assumed to have 
remained on their initial ART for the duration of follow-up.  
The Kaplan-Meier method and log-rank test were used to evaluate time to virologic 
failure by TDF use. Multivariable models were fit using Cox proportional hazards regression. 
Likelihood ratio test results comparing models with and without a time interaction term, as 
well as plots of the log of the cumulative hazards by time were examined to assess the 
proportional hazards assumption. Where this assumption was not met, the time following 
ART initiation was stratified at the point where the curves from the log of the cumulative 
hazards plot were no longer parallel. We confirmed the cut point by visually examining the 
plot of hazard ratios over time and by verifying the proportional hazards assumption was met 
on both sides of the cut point.121 All analyses were then performed for time included on 
either side of the 19-month cut point.  
Linear regression fit with generalized estimating equations was used to estimate the 
association between TDF use and CD4 count response. We used an independent correlation 
structure and robust standard errors to account for repeat CD4 count measures. Confounders 
were selected based on the existing literature, use of causal diagrams and change-in-estimate 
calculations.117,118 Continuous variables age, CD4 count, log10 HIV RNA level and creatinine 
level at the time of ART initiation were included in models using splines with four equal 
knots based on the case distribution.112 In all models we adjusted for CNICS site. 
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Because TDF was not available in all calendar years covered by these analyses and 
then prescribed widely to HBV co-infected patients, we performed three supplemental 
analyses. First, we repeated the analyses using calendar year of ART initiation as a proxy for 
the exposure. Second, we performed a sensitivity analysis using only data from 2002-2003. 
In these calendar years we observed some but not all patients with HBV infection receiving 
TDF. Third, we accounted for patients receiving zidovudine (AZT) or stavudine (D4T) in 
their initial ART regimen as discontinuation of ARV drugs known to have high toxicity 
levels can influence HIV outcomes. An additional sensitivity analysis was done for time to 
virologic failure where we assumed the five patients with no confirmatory HIV RNA 
measure >400 copies/mL did not fail. All tests for assessing statistical significance were 2-
sided with α=0.05.  All analyses were performed using SAS® version 9.2 (SAS Institute Inc., 
Cary, NC). 
 
Results 
Study Population 
 Of the 212 HIV/HBV co-infected patients, 6% were female, 46% were White, 43% 
Black and 11% of other races/ethnicities. The median age at ART initiation was 39 years 
(IQR: 33, 44) and the median year of ART initiation was 2004 (IQR: 2002, 2006). Sixteen 
percent of patients had a history of IVDU and 67% of patients were MSM (71% of men). At 
ART initiation 33% of patients had experienced a previous AIDS defining clinical condition 
and 14% were HCV co-infected.  The median pre-ART CD4 count, HIV RNA level and 
creatinine level were 128 cells/mm3 (IQR: 33, 294), 4.89 log10 copies/mL (IQR: 4.38, 5.34) 
and 0.9 mg/dL (IQR: 0.8, 1.0) respectively.  
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The 212 HIV/HBV co-infected patients were a subset of 3,706 HIV-infected patients 
who initiated ART meeting our inclusion criteria during the 11 years of this study and for 
whom (HBsAg) or HBV DNA results were available at ART initiation. HIV/HBV co-
infected patients differed from the 3,494 HIV mono-infected patients with respect to sex, 
MSM, initial ART regimen anchor drug and APRI. HBV co-infected versus HIV mono-
infected patients were 6% and 21% were women, 28% and 27% were non-MSM men, and 
66% and 52% were MSM men, respectively (all P < 0.001). Compared to HIV mono-
infected patients, HBV co-infected patients were less likely to receive a PI/r (15% versus 
23%, P=0.034) and more likely to have an APRI indicating liver damage (56% versus 28%, 
P < 0.001). No meaningful differences were observed by age, race/ethnicity, IVDU, year of 
ART initiation, AIDS defining clinical condition, HCV co-infection status, pre-ART CD4 
count, HIV RNA level, or creatinine level.  
 
Tenofovir Use 
Almost all HBV co-infected patients (n=209 of 212) received at least one anti-HBV 
agent as part of their initial ART; TDF alone (n=2, 1%), TDF with FTC or 3TC (n=129, 
61%), or FTC or 3TC alone (n=78, 37%). TDF use increased sharply from 20% in 2002 to 
50% in 2003 to > 90% for all subsequent study years. Among the 160 patients who began 
ART after 2001, 82% received TDF (Figure 6.1). The median year of ART initiation and 
follow-up time was 2001 (IQR: 2000, 2002) and 60 months (IQR: 26, 86) for patients 
without TDF, and 2006 (IQR: 2004, 2007) and 23 months (IQR: 16, 38) for patients with 
TDF (all P <0.001).  
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Factors associated with TDF use included no history of IVDU, no HCV co-infection at 
ART initiation, and ART initiation in more recent calendar years (Table 6.1). In 
multivariable analyses considering sex, MSM, history of IVDU, initial ART regimen anchor 
drug and HCV co-infection, no factors were independently predictive of TDF use (Table 
B.1). Repeating these analyses among patients who began ART in 2002 or 2003 yielded the 
same result.  
 
Tenofovir Effect on HIV RNA Response 
Among the 208 patients considered for analysis at 16 weeks post-ART initiation, 98, 
86, 60 and 43% remained under study observation through 6, 12, 24 and 36 months post-
ART initiation, respectively. At these 6-month intervals post-ART initiation the percent on 
ART was 86, 81, 77 and 82%, and the percent with suppressed HIV RNA levels was 68, 68, 
61 and 49%, and 32, 32, 39 and 51% among patients who did and did not receive TDF, 
respectively. 
 The cumulative probability of HIV virologic failure by 6, 12, 24 and 36 months 
following ART initiation was 10, 20, 25 and 29%. Compared to patients who received TDF, 
patients who did not receive TDF were more likely to experience HIV virologic failure 
following ART initiation (unadjusted HR=1.72, 95% CI: 1.02, 2.87, adjusted HR=1.59, 95% 
CI: 0.91, 2.80) (Table 6.2, Figure 6.2). The proportional hazards assumption was not met for 
all time following ART initiation. Rather, the effect of TDF on HIV virologic failure varied 
across time, with a clear change in estimate at 19 months post-ART initiation. Between 16 
weeks and 19 months following ART initiation, not receiving TDF conferred a greater risk of 
HIV virologic failure (HR=2.64, 95% CI: 1.45, 4.79). This result was consistent after 
 61 
 
 
adjusting for confounders (adjusted HR=2.31, 95% CI: 1.20, 4.45). However, among patients 
who achieved and maintained HIV virologic suppression through 19 months of therapy 
(n=118), the use of TDF did not appreciably affect HIV virologic failure post-19 months of 
ART (unadjusted HR=0.44, 95% CI: 0.15, 1.31; adjusted HR=0.37, 95% CI: 0.09, 1.48). 
Considering the five patients with no confirmatory HIV RNA measures as not having failed 
virologically did not alter inferences. 
 The risk of HIV virologic failure was greater in earlier calendar years of ART 
initiation (Figure 6.3). The unadjusted HRs for years 1998-1999, 2000-2001 and 2002-2005 
in comparison to 2006-2008 were 2.80 (95% CI: 1.23, 6.39), 2.23 (95% CI: 1.11, 4.47) and 
1.35 (95% CI: 0.69, 2.63), respectively. The effect of TDF use on HIV virologic failure 
among patients starting ART in 2002-2003 (n=41) was consistent with those observed in our 
primary analyses, as was the effect of TDF use on HIV virologic failure adjusted for AZT 
and D4T use.  
 
Tenofovir Effect on CD4 Count Response 
The median CD4 count at ART initiation was 137 cells/mm3 for the 131 patients with 
TDF use and 119 cells/mm3 for the 81 patients without TDF use (P=0.451). Median CD4 
counts increased for all patients following ART initiation; however, no significant 
differences were seen between patients with and without TDF use (Supplemental Figure 
6.1A). After adjustment for ART initiation age, race/ethnicity, sex, MSM, IVDU, initial 
ART, AIDS defining clinical condition, HCV co-infection, APRI, CD4 count, HIV RNA 
level and creatinine level patients without TDF use had an average difference in CD4 across 
time from ART initiation of -22 cells/mm3 (95% CI: -57, 13) compared to patients with TDF 
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use (Supplemental Table 6.1). Our findings did not change when we considered only the 
subset of patients who achieved and maintained HIV virologic suppression (n=164) 
(Supplemental Figure 6.1B). 
 
Discussion 
In this large US HIV clinical cohort we found that HIV/HBV co-infected patients who 
received TDF as part of their initial ART were more likely to achieve and maintain HIV 
RNA suppression over the first year and a half on therapy. Our findings support current US 
treatment guidelines which recommend treating HIV/HBV co-infected patients with 
combination regimens that include TDF. To date treatment recommendations were largely 
based on evidence of TDF activity against HBV. These findings suggest that TDF use may 
also lead to better HIV outcomes among HIV/HBV co-infected patients.  Identifying the 
optimal therapeutic management of HIV/HBV co-infected patients is not only relevant to 
individuals living in the US, it is also increasingly relevant to areas of the world where HBV 
is endemic and modern ART is increasingly available.147,148  
Among patients who achieved and maintained suppressed HIV RNA through the first 
year and a half on ART, TDF use did not appear to further affect the risk of HIV virologic 
failure. This is consistent with clinical and clinical trial observations that once virologic 
suppression is achieved virologic failure is uncommon, even with regimens that may not be 
considered optimal.120 However, it is possible that our inability to detect a difference after the 
first year and a half on ART could be due to calculating period-specific hazard ratios rather 
than cumulative measures. Period-specific hazard ratios do not account for possible selection 
bias caused by differential depletion over time of exposed and unexposed patients susceptible 
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to virologic failure.149 In addition, our ability to detect more subtle differences after sustained 
successful response to initial ART was restricted by available sample size and the limited 
number of HIV virologic failures observed. Consequently any conclusions about longer term 
effects of TDF use on HIV RNA response would require additional follow-up time in a larger 
cohort of patients. While we included many of the known predictors of HIV outcomes in our 
analyses, unmeasured confounders may lead to bias in our estimates.  
The CNICS clinical cohort is one of the largest US cohort studies and has a national 
distribution of study sites, with a diverse patient population and demographic composition 
that is largely consistent with national figures.135 In this group of patients we observed a 
rapid uptake of TDF as it became available for clinical use in the US, with essentially all 
HBV co-infected patients receiving TDF with either 3TC or FTC after 2003. This rapid 
uptake of TDF use limited our ability to account for calendar year differences in assessing 
the effect of TDF use on HIV response; however, the improvement in HIV RNA responses 
across calendar years of ART initiation were striking and highly coincident with the uptake 
of TDF use. Therefore we repeated our analysis among patients who began ART in 2002 and 
2003, during which time there was some heterogeneity in TDF use. These findings supported 
our primary results, although were imprecise due to the reduced sample size. Coincident to 
the rapid uptake of TDF among patients in our study was the discontinuation of other ARV 
drugs known to have high toxicity levels, in particular AZT and D4T. Therefore the better 
HIV virologic outcomes we observed for patients receiving TDF in initial ART may in part 
be due to less tolerable drugs being discontinued and/or replaced. In additional analyses we 
accounted for patients receiving AZT or D4T and although the effect of TDF on HIV 
response was somewhat lessened, our conclusions were unchanged. 
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Our results are consistent with a couple of smaller studies conducted to date. For 
example, two studies designed to evaluate the effect of TDF on HBV outcomes among 
HIV/HBV co-infected patients reported that patients who received TDF had superior HIV 
RNA response rates, but no differences were observed in CD4 count outcomes.125,133 We also 
did not find evidence that TDF use was associated with improved CD4 count responses; 
however, other large prospective randomized trials have observed a small rise in CD4 count 
with TDF/FTC and Efavirenz compared to other therapies.150 Furthermore, in this study we 
were unable to assess whether TDF use was associated with clinical HIV progression, as 
measured by either new AIDS defined clinical conditions or mortality, or with drug-related 
toxicity as measured by changes in renal function. Further longitudinal follow-up with a 
larger sample size would support these additional analyses, providing clinical endpoint 
evidence and strengthening evidence for guidelines in developed and developing regions.  
Treatment for HIV/HBV co-infection is more complex than treatment for either HIV or 
HBV alone.  It must balance multiple factors, such as the likelihood of response to anti-HBV 
therapy, the need to treat HIV, the prevention of drug resistance, minimizing the risk of drug-
induced hepatotoxicity and managing rising liver transaminases when they occur.  Additional 
issues complicating treatment for co-infected patients are the limited choice of anti-HBV 
drugs and that treatment for both infections is suppressive rather than curative, and therefore 
must be provided for long, often indefinite, periods.36  Data are limited whether TDF alone or 
in combination with 3TC/FTC is superior for improving HBV-related outcomes among HBV 
mono-infected patients and long-term HIV-related outcomes among HIV/HBV co-infected 
patients.124,151 We were unable to test for this difference as nearly everyone received TDF 
with either 3TC or FTC. 
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In summary, among HIV/HBV co-infected patients TDF use was associated with 
greater HIV RNA control early after ART initiation. Our study provides evidence that in 
addition to improving HBV outcomes, TDF use among HIV/HBV co-infected patients 
improves HIV outcomes. Our findings further support current US treatment guidelines and 
aid in identifying optimal therapy for HIV/HBV co-infected individuals who reside in 
developing settings. 
 
 66 
 
 
TABLE 6.1. Patient characteristics by tenofovir use at antiretroviral therapy initiation among 
HIV and hepatitis B co-infected patients, Center for AIDS Research Network of Integrated 
Clinical Systems 1998-2008 
       
 Tenofovir No Tenofovir   
Characteristic N  (%) N  (%)  P-value 
       
       Total 131  (62) 81 (38)   
 
      
Age in years, median (IQR) 39 (32, 44) 39 (35, 43)     0.856 
 
      
White race/ethnicity 62 (63) 36 (37)     0.682 
 
      
Sex and MSM       
     Male MSM 91 (65) 50 (35)     0.176 
     Male non-MSM 31 (53) 28 (47)   
     Female 9  (75) 3 (25)   
 
      
IVDU 13 (39) 20 (61)     0.004 
 
      
Year of ART initiation       
     2005-2008 96 (98) 2 (2)  < 0.001 
     2002-2004 35 (56) 27 (44)   
     1998-2001 0 (0) 52 (100)   
 
      
Type of initial ART*       
     PI 26 (51) 25 (49)     0.130 
     PI/r 23 (72) 9 (28)   
     NNRTI 82 (64) 47 (36)   
 
      
AIDS defining clinical condition 42 (59) 29 (41)     0.575 
 
      
HCV co-infection 9 (31) 20 (69)  < 0.001 
 
      
APRI > 0.5 70 (59) 49 (41)     0.314 
 
      
CD4 count (cells/mm3), 
median (IQR) 137 (30, 297) 119 (35, 255) 
 
   0.451 
 
      
HIV RNA level (log10 copies/ml), 
median (IQR) 4.83 (4.38, 5.23) 4.92 (4.38, 5.47) 
 
   0.495 
 
    
 
 
Creatinine (mg/dL), median (IQR) 1.00 (0.80, 1.10) 0.90 (0.80, 1.00)     0.158 
       
       
 
NOTES: HBV=hepatitis B virus; IQR= interquartile range; MSM=men who have sex with men; 
IVDU=intravenous drug use; ART= antiretroviral therapy; PI=protease inhibitor, PI/r=ritonavir-boosted 
protease inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; HCV=hepatitis C virus; APRI=AST-
platelet Ratio Index 
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TABLE 6.2. The effect of tenofovir use at antiretroviral therapy initiation on HIV virologic 
failure among 208 HIV and HBV co-infected patients, Center for AIDS Research Network of 
Integrated Clinical Systems 1998-2008 
        
 
 HR (95% CI) [P-value]  
 
 Time from ART initiation*  
 All time   0-19‡ months  > 19‡ months  
        
        Unadjusted        
Tenofovir           No 1.72 (1.02, 2.87) 0.040  2.64 (1.45, 4.79) 0.001 0.44 (0.15, 1.31) 0.140 
                                 Yes 1   1  1  
   
     
Adjusted†        
Tenofovir           No 1.59 (0.91, 2.80) 0.106  2.31 (1.20, 4.45) 0.012 0.37 (0.09, 1.48) 0.160 
                                 Yes 1   1  1  
        
        * Models fit with Cox proportional hazards regression 
† Models adjusted for age, race/ethnicity, sex, HIV exposure, initial antiretroviral therapy, AIDS defining clinical condition, 
hepatitis C co-infection, pre-therapy AST-platelet Ratio Index, pre-therapy CD4, pre-therapy HIV viral load, pre-therapy 
creatinine level and CNICS site 
‡ 19 months following ART initiation is the stratification point for which time on both sides satisfies the proportional hazards 
assumption  
NOTES: ART= antiretroviral therapy; HR=hazard ratio; CI=confidence interval 
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FIGURE 6.1. HIV and HBV co-infected patients by year of antiretroviral therapy initiation and tenofovir use, Center for AIDS 
Research Network of Integrated Clinical Systems 1998-2008 
  Calendar Year 
 Total 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
No tenofovir, n 81 7 10 19 16 16 11 0 0 2 0 0 
Tenofovir, n 131 0 0 0 0 4 11 20 25 24 28 19 
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FIGURE 6.2. Time from antiretroviral therapy initiation to HIV virologic failure stratified by 
tenofovir use among 208 HIV and HBV co-infected patients, Center for AIDS Research Network 
of Integrated Clinical Systems 1998-2008  
 
 
No tenofovir               
N total   78 67  52  50  36  34  30 
N event (cumulative)   9  22  23  27  28  28 
               
Tenofovir              
N total  130 120  95  80  51  41  27 
N event (cumulative)   8  16  17  19  20  22 
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FIGURE 6.3. Time from antiretroviral therapy initiation to HIV virologic failure stratified by 
year of initiation among 208 HIV and HBV co-infected patients, Center for AIDS Research 
Network of Integrated Clinical Systems 1998-2008 
 
N 1998-1999  16 12  9  9  7  6  5 
N 2000-2001  34 29  22  21  16  16  15 
N 2002-2004  60 54  48  47  34  31  28 
N 2005-2008  98 92  68  53  32  23  10 
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SUPPLEMENTAL TABLE 6.1. The effect of tenofovir use on CD4 counts across time 
following antiretroviral therapy initiation among HIV and HBV co-infected patients, Center 
for AIDS Research Network of Integrated Clinical Systems 1998-2008 
         
 
Average difference in CD4 count (cells/mm3) (95% CI) [P-value] 
 
 All patients 
(n=212) 
 HIV RNA suppressed patients 
(n=164) 
 
         
         Unadjusted         
Tenofovir                No -55 (-114, 3)  0.065  -46 (-105, 13)  0.126  
                                                  Yes 1    1    
        
Adjusted for pre-therapy CD4 count      
 
  
Tenofovir                No -29 (-63, 5)  0.096  -25 (-63, 13)  0.201  
                                                  Yes 1    1    
        
Fully adjusted†         
Tenofovir                No -22 (-57, 13)  0.215  -13 (-52, 26)  0.522  
                                                  Yes 1    1    
         
         * Models fit with linear regression fit with generalized estimating equations. An independent correlation structure and 
robust standard errors were used to account for repeat CD4 measures. 
† Models adjusted for age, race/ethnicity, sex, HIV exposure, initial antiretroviral therapy, AIDS defining clinical 
condition, hepatitis C co-infection, pre-therapy AST-platelet Ratio Index, pre-therapy CD4, pre-therapy HIV RNA level, 
pre-therapy creatinine level and CNICS site. 
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SUPPLEMENTAL FIGURE 6.1. Box and whisker plots of CD4 counts at 6 month 
intervals following antiretroviral therapy initiation by tenofovir use among HIV and HBV co-
infected patients, Center for AIDS Research Network of Integrated Clinical Systems 1998-
2008: (A) all patients (n=212); and (B) patients who achieved and maintained HIV RNA 
suppression (n=164)  
(A) 
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CHAPTER SEVEN: DISCUSSION 
 
Summary of Findings 
In this project we described several findings which bring new light to current published 
literature on HIV/HBV co-infection. In our first specific aim, we found a substantial decrease 
in more recent calendar years of early mortality following ART initiation among HIV/HBV 
co-infected patients. HBV-infected patients who began therapy between 1998 and 2001 were 
over twice as likely to die in the first two years following therapy initiation compared to 
HBV-uninfected patients, but this difference attenuated in more recent calendar years, with 
no difference in time to death by HBV infection status among patients starting ART between 
2005 and 2008. These findings suggest that during the first two years following ART 
initiation, HBV co-infection may no longer increase the risk of all-cause mortality among 
HIV-infected individuals.  
 In our second specific aim, we found that HIV/HBV co-infected patients who 
received TDF as part of their initial ART were more likely to achieve and maintain HIV 
RNA suppression over the first year and a half on therapy. Among patients who achieved and 
maintained suppressed HIV RNA during this interval, TDF use did not appear to further 
affect the risk of HIV virologic failure. This is consistent with clinical and clinical trial 
observations that once virologic suppression is achieved virologic failure is uncommon, even 
with regimens that may not be considered optimal.120 However, our ability to detect more 
subtle differences after sustained successful response to initial ART was restricted by 
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available sample size and the limited number of HIV virologic failures observed. 
Consequently any conclusions about longer term effects of TDF use on HIV RNA response 
would require additional follow-up time in a larger cohort of patients. 
These findings are reassuring, particularly since we observed no decrease in the 
prevalence of HBV co-infection across the study period. However, while we found that HBV 
co-infection does not contribute to liver-related mortality in the short-term, whether HBV co-
infection accounts for some of the rise in liver-related mortality in the long-term remains 
unknown.  
 
Strengths and Limitations 
A major limitation of our analyses was rapid and widespread uptake of ARVs 
efficacious for treatment of both HIV and HBV, in particular TDF with FTC or 3TC. Even in 
this large cohort, the small number of HBV co-infected patients and the lack of heterogeneity 
in treatment over calendar time meant we could not measure the extent to which these anti-
HBV agents were responsible for the decrease in early mortality and the improvement in HIV 
viral control separate from the collective improvements in the management of HIV patients 
between the late 1990s and late 2000s. However, we ruled out the contribution of several 
competing explanations, including changes in patient demographic and clinical 
characteristics over calendar time.  
Our studies are, to date, the largest to explore HIV outcomes and mortality among 
HIV/HBV co-infected individuals. Also, our study population is largely representative of the 
HIV-infected population in the US, supporting the generalizability of our findings. Finally, 
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our studies are, to the best of our knowledge, the first to capture and document the rapid 
uptake of ARVs efficacious for treatment of both HIV and HBV.  
 
Clinical and Public Health Significance 
HBV has been recognized as a significant cause of morbidity and mortality in HIV-
infected patients.2,47,145 An effective vaccine against HBV has been available in the US for 
nearly 30 years; however, a substantial proportion of high-risk individuals have not been 
immunized.139 
As we found in the CNICS cohort with the prevalence of HBV infection steady at 6% 
between 1998 and 2008, preventive efforts have not yet been successful at reducing HBV 
infection among HIV-infected individuals. For these reasons, effective HBV treatment 
remains a high priority for HIV care.  
Treatment for HIV/HBV co-infection is more complex than treatment for either HIV or 
HBV alone. It must balance multiple factors, such as the likelihood of response to anti-HBV 
therapy, the need to treat HIV, the prevention of drug resistance, minimizing the risk of drug-
induced hepatotoxicity and managing rising liver transaminases when they occur. Additional 
issues complicating treatment for co-infected patients are the limited choice of anti-HBV 
drugs and that treatment for both infections is suppressive rather than curative, and therefore 
must be provided for long, often indefinite, periods.36 Though a limitation for our analyses, it 
is important to recognize that timely and extensive uptake of improved treatment, as we 
observed in the CNICS cohort, has large clinical and public health benefits. 
Our findings support current US treatment guidelines which recommend treating 
HIV/HBV co-infected patients with combination regimens that include agents efficacious for 
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both HIV and HBV, in particular TDF. To date treatment recommendations were largely 
based on evidence of TDF activity against HBV. These findings suggest that TDF use may 
also lead to better HIV outcomes and to improvements in short-term mortality among 
HIV/HBV co-infected patients.  
In the US and other developed settings the prevalence of HBV is not high, even among 
HIV-infected individuals. But in resource limited settings, the story is different. Worldwide 
two billion people have been infected with HBV and nearly 400 million live with chronic 
infection.13 The geographic areas with the largest burden of HBV are the same as those with 
the largest burden of HIV, and given shared risk factors, co-infection is common. Therefore 
our findings have important implications for prioritizing treatment in these areas. They also 
provide evidence that increasing the utilization of agents efficacious for both HIV and HBV 
may substantially improve HIV-related outcomes and short-term mortality for a great number 
of people. 
 
Future Directions 
In the presence of resistance evolution ongoing efforts to identify new agents with 
activity against both HIV and HBV is necessary.136-138 Further, effective treatment is not a 
substitute for prevention. Since HBV infection can occur before, after or concurrent with 
HIV infection, and because HBV vaccine-induced immunity is compromised in HIV-infected 
patients140, it is vital that efforts continue to achieve wide-spread uptake of HBV vaccination 
through routine and other immunization opportunities.141 
 Additional work on mortality by HBV status is necessary to determine whether the 
improvement in mortality we observed during the first two years following therapy initiation 
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is sustained for longer periods. This will need to occur in a cohort with longer follow-up of 
patients who were treated with modern therapy efficacious for both HIV and HBV. Further, 
additional work is indicated that considers response to agents with activity against both HIV 
and HBV on HIV RNA suppression, immunologic response, liver disease progression and 
liver-related mortality. Longer longitudinal follow-up with a larger sample size would 
support these additional analyses, providing clinical endpoint evidence and strengthening 
evidence for guidelines in developed and developing regions.  
 
Conclusions 
Aging up of the cohort of infants who began receiving HBV vaccine as part of the 
routine childhood immunization schedule, together with expanding overall coverage of HBV 
vaccine will hopefully bring the end of HIV/HBV co-infection in the US. Unfortunately, this 
same outcome will not be seen in resource limited settings for quite some time. Therefore 
understanding the most efficacious treatment options for HIV/HBV co-infected individuals is 
necessary in order to enable the least advantaged patients to have the best health outcomes 
possible. Efforts to expand the use of agents with activity against both HIV and HBV are 
needed, as well as careful monitoring to ensure the positive benefits seen in our studies, as 
well as those for HBV-related outcomes, are also seen for HIV/HBV co-infected patients 
living in resource limited settings. 
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APPENDIX A. RESULT OF LOG-LINEAR BINOMIAL REGRESSION MODEL OF 
HBV CO-INFECTION 
 
TABLE A.1. Patient characteristics associated with hepatitis B co-infection at antiretroviral 
therapy initiation among 3706 HIV-infected patients 1998-2008, CFAR Network of 
Integrated Clinical Systems  
      
 Full model*   Final model*  
Characteristic RR (95% CI) P-value  RR (95% CI) P-value 
      
      Sex and MSM      
     Male MSM 4.46 (2.47, 8.05) < 0.001  4.41 (2.44, 7.96) < 0.001 
     Male non-MSM 3.22 (1.75, 5.94)   3.26 (1.77, 6.01)  
     Female 1   1  
      
Type of initial ART      
     PI 1.05 (0.77, 1.44) 0.004  1.07 (0.79, 1.46) 0.007 
     PI/r 0.57 (0.39, 0.83)   0.59 (0.41, 0.86)  
     NNRTI 1   1  
      
AIDS defining clinical condition      
     Yes 1.27 (0.97, 1.68) 0.085    
     No 1     
      
APRI      
     > 0.5 3.07 (2.36, 3.99) < 0.001  3.12 (2.40, 4.05) < 0.001 
     ≤ 0.5 1   1  
      
      
 
* Full and final models fit with multivariable log-linear binomial regression and include all characteristics listed in respective 
column plus site. 
NOTES: RR=relative risk; 95% CI=95% confidence interval; MSM=men who have sex with men; ART= antiretroviral 
therapy; PI=protease inhibitor, PI/r=ritonavir-boosted protease inhibitor; NNRTI=non-nucleoside reverse transcriptase 
inhibitor; APRI=AST-to-platelet ratio index 
 
 
 
 79 
 
 
APPENDIX B. RESULT OF LOG-LINEAR BINOMIAL REGRESSION MODEL OF 
TDF USE 
 
TABLE B.1. Patient characteristics associated with tenofovir use at antiretroviral therapy 
initiation among 212 HIV/HBV co-infected patients 1998-2008, CFAR Network of 
Integrated Clinical Systems  
      
 Full model*   Final model*†  
Characteristic RR (95% CI) P-value  RR (95% CI) P-value 
      
      Sex and MSM      
     Male MSM 0.82 (0.47, 1.42) 0.475    
     Male non-MSM 0.83 (0.48, 1.43)     
     Female 1     
      
IVDU      
     Yes 0.84 (0.56, 1.25) 0.389    
     No 1     
      
Type of initial ART      
     PI 0.81 (0.62, 1.06) 0.122    
     PI/r 1.06 (0.82, 1.37)     
     NNRTI 1     
      
HCV co-infection      
     Yes 0.66 (0.41, 1.08) 0.100    
     No 1     
      
      
 
* Full and final models fit with multivariable log-linear binomial regression and include all characteristics listed in respective 
column plus site. 
† No covariables were independently associated with tenofovir use. 
NOTES: RR=relative risk; 95% CI=95% confidence interval; MSM=men who have sex with men; IVDU=intravenous drug 
user; ART= antiretroviral therapy; PI=protease inhibitor, PI/r=ritonavir-boosted protease inhibitor; NNRTI=non-nucleoside 
reverse transcriptase inhibitor; HCV=hepatitis C virus 
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